BioMark Diagnostics Announces Uplisting to OTCQB Venture Market
Milestone strengthens transparency and credibility as the Company advances commercialization of its metabolomics technology platform Vancouver, British Columbia – (May 8th, 2025) BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (OTCQB: BMKDF) (FSE: 20B), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that its common shares have […]
Form 7 Monthly Progress Report April 2025
Form 7 Monthly Progress Report May 2025 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 105,090,213 May 1, 2025 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
Form 7 Monthly Progress Report March 2025
Form 7 Monthly Progress Report February 2025 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 105,090,213 April 5, 2025 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BioMark Announces the Final Closing of Oversubscribed Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. BioMark Announces the Final Closing of Oversubscribed Private Placement Vancouver, British Columbia – (March 31, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, today announced the […]
BioMark Secures Financing for Initial Tranche to Advance Early-Detection Oncology Testing Platform
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. BioMark Secures Financing for Initial Tranche to Advance Early-Detection Oncology Testing Platform Vancouver, British Columbia – (March 26, 2025) BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, is […]
Remembering Mia Love: A Trailblazer’s Legacy and Biomark’s Fight Against Cancer
Personal Reflection: A Shared Journey of Loss and Hope My journey with BioMark Diagnostics is deeply personal. Two years ago, I lost my sister in the UK to glioblastoma (GBM), a journey that began with breast cancer that tragically metastasized to her brain. I flew to London, spending the last six weeks by her side, […]
BioMark Diagnostics Underscores Commitment to Rare DiseaseResearch on Rare Disease Day 2025
BioMark Diagnostics Underscores Commitment to Rare Disease Research on Rare Disease Day 2025 BioMark is pioneering liquid biopsy solutions for challenging conditions and championing equity in diagnosis Vancouver, British Columbia – (February 28, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early cancer […]
Form 7 Monthly Progress Report February 2025
Form 7 Monthly Progress Report February 2025 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 90,886,229 March 4, 2025 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
From Black Plastics to Biomarkers How Environmental Causes of Cancer Can Be Prevented
From Black Plastics to Biomarkers How Environmental Causes of Cancer Can Be Prevented Seemingly harmless environmental factors in our homes can contribute to cancer risk. What you can do about it? Learn about the dangers of toxic chemicals like flame retardants and PFASs found in common household items such as plastic utensils and non-stick pans. […]
Form 7 Monthly Progress Report January 2025
Form 7 Monthly Progress Report January 2025 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 90,886,229 February 3, 2025 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]